Information Provided By:
Fly News Breaks for April 8, 2016
ICPT
Apr 8, 2016 | 07:34 EDT
Oppenheimer analyst Carlos Solorzano expects the FDA to approve Intercept Pharmaceuticals' Ocaliva on May 29th and anticipates "good uptake" of the drug based on the positive opinion of key opinion leaders about its efficacy, safety and tolerability. Yesterday, the Gastrointestinal Drugs Advisory Committee of the FDA recommended unanimously the approval of Ocaliva for the treatment of patients with primary biliary cirrhosis, recently renamed primary biliary cholangitis, the analyst told investors in a research note. Solorzano reiterates an Outperform rating and $309 price target on the shares.
News For ICPT From the Last 2 Days
There are no results for your query ICPT